You just read:

Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor Valbenazine

News provided by

Neurocrine Biosciences, Inc.

Aug 31, 2016, 16:02 ET